• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Medical Device Market
    Medical Device News
    Medical Device Stocks
    • Medical Device Market
    • Medical Device News
    • Medical Device Stocks
    market news

    DNA Nanobots to Target Cancer Cells in First Human Trial

    Vivien Diniz
    Jan. 04, 2016 09:46AM PST
    Medical Device Investing

    3Tags reported that Professor Ido Bachelet of Israel’s Bar-Ilan University confirmed that nanobots capable of fighting cancerous cells no longer a thing of science fiction.

    3Tags reported that Professor Ido Bachelet of Israel’s Bar-Ilan University confirmed that nanobots capable of fighting cancerous cells no longer a thing of science fiction. Indeed, the first DNA nanobot trial in a human subject will take place in 2016.
    According to the report:

    Nanobots can also have multiple “payloads” in them, and can be programmed so that they know which drug to expose to specific molecules. This means that nanobots work well in combination therapy—where multiple drugs are used at once—and can be timed so that the different drugs don’t interfere with one another. As of December 2014, the nanobots that Bachelet’s team have developed can recognize 12 different types of cancerous cells.

    3Tags also notes that:

    In that case, when can we expect this miracle treatment to hit the public? The first DNA nanobot trial in a human subject will take place this year—in fact, it could be happening right now—on a person with late-stage leukemia. The patient is expected to die, but Bechelet believes that, based on previous animal trials, the nanobots can remove the cancer in the span of a month. If the trial goes well, we could see nanotechnology hit the public in one-to-five years.”

     

    Click here to view the full article. 

    ido bacheletmarket news
    The Conversation (2)
    Huy Lam
    Huy Lam
    27 Nov, 2017
    Please let me know where I can access this treatment. And how to invest in this chanel
    0 Replies Hide replies
    Show More Replies
    Huy Lam
    Huy Lam
    27 Nov, 2017
    Please let me know where I can access this treatment. And how to invest in this chanel
    0 Replies Hide replies
    Show More Replies

    Go Deeper

    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Latest News

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×